Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent-Reference-Cited by-同舟云学术

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Published:2009-05 Issue:2 Volume:64 Page:211-218
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Carteni G.,Manegold C.,Garcia G. Martin,Siena S.,Zielinski C.C.,Amadori D.,Liu Y.,Blatter J.,Visseren-Grul C.,Stahel R.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data from 1973 through 2003;Price;Am J Epidemiol,2004

2. Clinical presentation and natural history of benign and malignant mesothelioma;Antman;Semin Oncol,1981

3. Pemetrexed in malignant pleural mesothelioma;Hazarika;Clin Cancer Res,2005

4. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference;Hassan;Ann Oncol,2006

5. The European mesothelioma epidemic;Peto;Br J Cancer,1999

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is Extereme Cytoreductive Surgery Beneficial To Survival In Malignant Peritoneal Mesothelioma?;Acta Chirurgica Belgica;2024-01-31

2. Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS–HIPEC;Annals of Surgical Oncology;2023-11-08

3. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-09

4. 2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma;Annals of Surgical Oncology;2023-07-23

5. Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform;Scientific Reports;2023-07-19